IL141515A - Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same - Google Patents

Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same

Info

Publication number
IL141515A
IL141515A IL14151599A IL14151599A IL141515A IL 141515 A IL141515 A IL 141515A IL 14151599 A IL14151599 A IL 14151599A IL 14151599 A IL14151599 A IL 14151599A IL 141515 A IL141515 A IL 141515A
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical composition
same
optically active
vascular diseases
Prior art date
Application number
IL14151599A
Other languages
English (en)
Other versions
IL141515A0 (en
Inventor
Urogdi Laszlo Barabas
Mihaly Marvanyos Ede
Denes Laszlo Jednakovitz
Andrea Kurucz Istvan
Bacsys Erno Korom
Zsuzsanna Nagy Zoltan
Urge Laszlo Szukbereky
Jeno Acsai Karoly Krajcs Peter
Original Assignee
Biorex Kutato Fejlesztoe Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejlesztoe Kft filed Critical Biorex Kutato Fejlesztoe Kft
Publication of IL141515A0 publication Critical patent/IL141515A0/xx
Publication of IL141515A publication Critical patent/IL141515A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL14151599A 1998-12-14 1999-12-07 Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same IL141515A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
IL141515A0 IL141515A0 (en) 2002-03-10
IL141515A true IL141515A (en) 2005-09-25

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14151599A IL141515A (en) 1998-12-14 1999-12-07 Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same

Country Status (27)

Country Link
US (1) US6384029B1 (pt)
EP (1) EP1147105B1 (pt)
JP (2) JP2002532498A (pt)
KR (1) KR100661774B1 (pt)
AT (1) ATE266027T1 (pt)
AU (1) AU765336B2 (pt)
BG (1) BG65179B1 (pt)
BR (1) BR9913982A (pt)
CA (1) CA2340734C (pt)
CZ (1) CZ300764B6 (pt)
DE (1) DE69917074T2 (pt)
DK (1) DK1147105T3 (pt)
EE (1) EE04551B1 (pt)
ES (1) ES2219091T3 (pt)
HR (1) HRP20010133B1 (pt)
HU (1) HU226617B1 (pt)
IL (1) IL141515A (pt)
NO (1) NO317649B1 (pt)
PL (1) PL196584B1 (pt)
PT (1) PT1147105E (pt)
RS (1) RS50129B (pt)
RU (1) RU2222538C2 (pt)
SI (1) SI1147105T1 (pt)
SK (1) SK285582B6 (pt)
UA (1) UA70340C2 (pt)
WO (1) WO2000035914A1 (pt)
ZA (1) ZA200101182B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514418A (ja) 2002-01-11 2005-05-19 ビオレックス クタトー エス フェイレストェー アールテー. カルボキサミジン誘導体及び血管疾患の治療におけるそれらの使用
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
ES2555908T3 (es) 2008-06-26 2016-01-11 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
KR20110084514A (ko) 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
EP3626255A1 (en) 2010-11-30 2020-03-25 Orphazyme A/S Methods for increasing intracellular activity of hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
ES2881860T3 (es) 2014-09-15 2021-11-30 Orphazyme As Formulación de arimoclomol
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
BR112018070653A2 (pt) 2016-04-29 2019-02-05 Orphazyme As ingrediente farmacêutico ativo, e, composição
CN110753544A (zh) 2017-05-24 2020-02-04 奥菲泽米有限公司 热激蛋白诱导物和额颞病况
KR20210015790A (ko) 2018-05-28 2021-02-10 오르파짐 에이/에스 질환의 바이오마커로서 pbmc 샘플에서 hsp70 단백질 수준
MX2023005954A (es) 2020-11-19 2023-09-04 Zevra Denmark As Procesos para preparar citrato de arimoclomol e intermediarios del mismo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
WO1997016349A1 (en) * 1995-11-03 1997-05-09 Global Trading Uk Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
SK2342001A3 (en) 2001-08-06
WO2000035914A1 (en) 2000-06-22
NO20012310D0 (no) 2001-05-10
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
PL196584B1 (pl) 2008-01-31
SK285582B6 (sk) 2007-04-05
CA2340734C (en) 2008-10-21
PL346767A1 (en) 2002-02-25
EP1147105A1 (en) 2001-10-24
YU25001A (sh) 2004-07-15
ATE266027T1 (de) 2004-05-15
NO317649B1 (no) 2004-11-29
RS50129B (sr) 2009-03-25
IL141515A0 (en) 2002-03-10
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
BR9913982A (pt) 2001-06-12
NO20012310L (no) 2001-05-10
HRP20010133A2 (en) 2002-02-28
ES2219091T3 (es) 2004-11-16
KR20010073129A (ko) 2001-07-31
CA2340734A1 (en) 2000-06-22
HRP20010133B1 (en) 2005-02-28
BG105342A (en) 2001-12-29
DK1147105T3 (da) 2004-06-01
JP2011201916A (ja) 2011-10-13
DE69917074D1 (de) 2004-06-09
DE69917074T2 (de) 2005-05-12
JP5620340B2 (ja) 2014-11-05
BG65179B1 (bg) 2007-05-31
HU226617B1 (en) 2009-04-28
PT1147105E (pt) 2004-07-30
JP2002532498A (ja) 2002-10-02
CZ20011550A3 (cs) 2001-08-15
EP1147105B1 (en) 2004-05-06
US6384029B1 (en) 2002-05-07
EE04551B1 (et) 2005-10-17
AU765336B2 (en) 2003-09-18
CZ300764B6 (cs) 2009-08-05
HUP9802897A2 (hu) 2000-11-28
UA70340C2 (en) 2004-10-15
AU1790600A (en) 2000-07-03
EE200100188A (et) 2002-08-15

Similar Documents

Publication Publication Date Title
TW262461B (pt)
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
IL109534A0 (en) Pour-on formulations containing polymeric material, glycols and glycerides and a process for their preparation
BG106155A (en) Novel derivatives and analogues of galanthamin
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
DK1492539T3 (da) Statin-terapi til forögelse af kognitiv funktion
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
ATE106732T1 (de) Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
FR2673105B1 (fr) Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
GEP20002141B (en) Use of 2-Phenyl-1, 2-Benzisoselenazol-3(2H)-One for Prevention and/or Treatment of Dementia, a Pharmaceutical Composition for Prevention and/or Treatment of the Alzheimer’s Disease
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees